Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Annexon, Inc. ANNX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
58/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$16.00
+175.9%

Annexon, Inc. (ANNX) is a Biotechnology company in the Healthcare sector, currently trading at $5.80. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ANNX = $16 (+175.9% upside).

Valuation: ANNX trades at a trailing Price-to-Earnings (P/E) of -4.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.19.

Net income is $207M (loss), growing at -16.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $26M against $212M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 5.68 (strong liquidity). Debt-to-assets is 9.4%. Total assets: $278M.

Analyst outlook: 10 / 10 analysts rate ANNX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$16.00
▲ 175.86% Upside
Average Price Target
The 12-month price target for Annexon, Inc. is $16.00.

ANNX SharesGrow Score Overview

70/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ANNX

✓
VALUE Pass
100/100
ANNX trades at a trailing Price-to-Earnings (P/E) of -4.6 (S&P 500 average ~25). Forward PEG 0.19 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $16, implying +175.9% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ANNX: +0%/yr revenue is, -16.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ANNX: Debt-to-Equity (D/E) ratio 0.12 (conservative), Current ratio is 5.68 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
ANNX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 10 / 10 analysts rate ANNX as buy (100%). Analyst consensus target is $16 (+175.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.285-7.18
Volume2.12M
Avg Volume (30D)2.6M
Market Cap$693.65M
Beta (1Y)1.15
Share Statistics
EPS (TTM)-1.34
Shares Outstanding$155.11M
IPO Date2020-07-24
Employees106
CEODouglas E. Love
Financial Highlights & Ratios
EBITDA$-213.76M
Net Income$-206.69M
Operating Income$-216.41M
Total Cash$238.35M
Total Debt$26.2M
Net Debt$-135.85M
Total Assets$277.57M
Price / Earnings (P/E)-4.3
Analyst Forecast
1Y Price Target$16.00
Target High$16.00
Target Low$16.00
Upside+175.9%
Rating ConsensusBuy
Analysts Covering10
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS03589W1027

Price Chart

Track all markets on TradingView
ANNX
Annexon, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.29 52WK RANGE 7.18

People Also View

KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 ISEE
ISEE
IVERIC bio, Inc.
$39.95
+0.38%
 GPCR
GPCR
Structure Therapeutics Inc.
$53.19
-1.95%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 RCUS
RCUS
Arcus Biosciences, Inc.
$23.01
+2.77%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message